Note: CellMosaic is currently accepting investments through StartEngine. Learn more at https://www.startengine.com/offering/cellmosaic
Breaking Ground: A New Patent for Better Medicine
Innovation in biotech often starts with a document that represents years of research. Here, that document is a USPTO notice of allowance for our newest patent, held proudly by our founder and CEO Dr. Yumei Huang. This patent for branched high-loading AqueaTether® linker technologies emerged from our Department of Defense research collaboration, marking another milestone in our mission to improve drug delivery.
Precision in Every Step
Advanced Purification Technologies
In our analytical lab, our Chief Scientific Officer Dr. Subi Dey operates our Agilent preparative HPLC system with practiced precision. This sophisticated purification process ensures our small molecule drugs meet the exacting standards required for bioconjugation research. Each successful purification brings us closer to our goal of more effective targeted therapies.
Innovative Filtration Processes
At the adjacent station, scientist Katie monitors the µPULSE-TFF system, carefully purifying fluorescent-labeled antibodies. This advanced tangential flow filtration technology represents a crucial step in our bioconjugation process. The purified antibodies will become part of the targeted therapeutics that could help reduce the devastating side effects often associated with treatments like chemotherapy.
From Liquid to Stable Form
Preservation and Stability
Across the room, scientist Annie prepares protein conjugates for lyophilization. Each tray of fluorescent dye-labeled bioconjugates requires precise handling - the freeze-drying process is critical for maintaining product stability. This step transforms liquid solutions into stable, powder forms that researchers can reliably use in their development work.
Quality Control and Shipment
Precision Packaging
In our fulfillment area, Katie meticulously prepares ADC vial shipments. Each of the seven boxes she packs contains more than just products - they carry the potential for advancement in targeted therapeutics. These shipments will support research at some of the 500+ organizations worldwide using our technology to develop better treatments.
Temperature-Controlled Storage
Dr. Huang personally oversees our most sensitive storage protocols. At the -80°C freezer, she retrieves products with the same methodical attention that led her to develop over 220 proprietary bioconjugation methods. Her innovations in chemical technologies have transformed how researchers approach drug delivery challenges, making powerful medicines work better by delivering them precisely where they're needed.
Preparing for Tomorrow's Research
Final Quality Checks
Production specialist John conducts final inspections of our PerKit™ products before careful refrigeration. Each kit represents CellMosaic's commitment to providing researchers with reliable, effective tools for developing targeted therapies. The temperature-controlled storage ensures that products maintain their integrity until they reach research labs around the world.
The Bigger Picture: Impact Beyond Our Lab
From Basic Research to Breakthroughs
Our work supports multiple stages of drug development:
- Basic research tools that enable initial discovery
- Custom manufacturing services that advance promising candidates
- Specialized processes that help scale successful approaches
- Quality control systems that ensure consistent results
Global Research Impact
Our technology and products now support research across multiple therapeutic areas:
- Cancer treatment advances at Massachusetts General Brigham
- NIH-funded vaccine development for opioid addiction at the University of New Mexico
- Specialized drug development at the German Cancer Research Center (DKFZ)
- Complex bioconjugation work with IBEX Biosciences
- Innovative applications in food safety testing at Reveal Foods
Looking Forward: The Future of Drug Delivery
Growing Market Presence
Our commitment to advancing drug delivery science has attracted partners from leading research institutions including Stanford and Yale. The global ADC market is projected to reach more than $40 billion by 2029, growing at 22% CAGR. Beyond ADCs, our technology has applications across the broader drug delivery market - from opioid addiction treatment to diabetes - representing a combined opportunity exceeding $200 billion globally.
Continuing Innovation
Every day at CellMosaic builds upon our foundation of scientific excellence. From Dr. Huang's groundbreaking work in bioconjugation to our team's dedication to quality, we're advancing the science of drug delivery across multiple therapeutic areas. While we're proud of our growth and market validation, what truly drives us is knowing that each advance in our technology could mean better outcomes for patients.
As we continue to expand our capabilities and reach, we remain focused on our core mission: making powerful medicines work better by delivering them precisely where they're needed. Every product that leaves our facility carries with it the potential to advance this mission.
Interested in joining our mission to transform drug delivery science? Learn more about investing in CellMosaic at https://www.startengine.com/offering/cellmosaic
This Reg CF offering is made available through StartEngine Primary, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.